Most people never think about where a medicine actually begins. It doesn't begin at the pharmacy counter, or on the factory line, or even in the vial. It begins with a molecule – a key starting material, in the industry's language. Get that ingredient wrong, or lose access to it, and everything downstream stops. The finished dose doesn't matter if the thing it's made from is stuck on a boat, sole-sourced from a single overseas plant, or simply unavailable when a hospital needs it.

That is the part of the chain Occam was built for. In the End-to-End Commercialization Project, Occam will accelerate the development of domestically sourced key starting materials – the foundational chemical inputs that everything else depends on. Phlow Corp. will advance domestic active pharmaceutical ingredient (API) manufacturing. Civica, Inc. will lead finished dose formulation, FDA approval, commercial manufacturing, and delivery to patients. Three partners, one continuous line from the raw material to the bedside.

Why this project, and why now

Today, more than 130 million Americans rely on medicines produced through global manufacturing networks that have grown longer, more opaque, and more fragile with every passing year. Decades of offshoring didn't just move factories overseas – they moved technical expertise, innovation, and, critically, the sourcing of the ingredients themselves. Shortages of essential therapies have become a recurring feature of American healthcare rather than an anomaly.

The four medicines at the center of this project make the stakes concrete. Ketamine, midazolam, norepinephrine, and succinylcholine are sterile injectables used every single day in emergency rooms, anesthesia, and critical care. These are not niche compounds. They are the drugs a clinician reaches for when there is no time to wait – which is exactly why a supply chain that can go dark without warning is unacceptable.

The project rests on serious groundwork. It builds on more than $1.7 billion in prior federal, state, philanthropic, and private investment that established the Tech Hub, and on nearly $14 billion in commitments across the broader ecosystem since 2020. In 2025 alone, Virginia announced more than $13 billion in advanced pharmaceutical manufacturing investment, including major commitments from AstraZeneca, Eli Lilly, and Merck.

Occam's role: command of the input

It's not only what you make. It's how you source what makes it. That has been Occam's position from day one, and this project is that thesis put to work on some of the most important medicines in the country.

Sourcing key starting materials domestically is not a matter of placing a different order. It means qualifying suppliers, building redundancy before it's needed, and pipelining new sources so that no single point of failure can hold a medicine hostage. It means seeing disruption coming and having a Plan B – through Z – already in place. That's the difference between a supply chain that reacts to a crisis and one that has already routed around it.

“Building a resilient end-to-end pharmaceutical supply chain in the U.S. is a complex puzzle. We are pleased to partner with some of the best in the industry to meet this incredibly difficult challenge”

— James K. Ferri, CEO + Founder, Occam Systems

What makes the End-to-End model powerful is that Occam's command of the molecule doesn't sit in isolation. It connects directly to Phlow's API manufacturing and Civica's finished-dose commercialization. Each partner's strength compounds the next. The result is what a resilient medicine supply chain should have looked like years ago: integrated, domestic, and built to move faster than the disruption.

What the integrated pathway connects:

• Domestically sourced key starting materials – Occam Systems

• Domestic active pharmaceutical ingredient (API) manufacturing – Phlow Corp.

• Finished dose formulation, FDA approval, commercial manufacturing, and patient delivery – Civica, Inc.

Behind those three names stand more than 55 Alliance partners spanning industry, academia, workforce development, government, nonprofits, and economic development – a coalition that, in the words of its leadership, chose collaboration over competition to build something larger than any one organization could accomplish alone.

A Richmond story with national stakes

This work is happening in Occam's backyard. Richmond, Virginia is fast becoming the center of gravity for advanced pharmaceutical manufacturing in the United States, and the Commonwealth is emerging as a national leader in the field. State leadership has framed the EDA investment as a vote of confidence in Virginia's future – one expected to create jobs, encourage innovation, and strengthen the nation's pharmaceutical manufacturing ecosystem.

For Occam, that proximity isn't incidental. Rebuilding a domestic supply chain is easier when the people doing the sourcing, the API manufacturing, and the finished-dose work are close enough to move as one system rather than a chain of hand-offs. It's the operating-system approach applied to a region: one source of truth, one step ahead.

The bigger picture

The difference between winning and losing in today's world increasingly comes down to one thing: sourcing the ingredients the world needs most. In most industries that's a competitive edge. In medicine, it's a matter of whether the drug is on the shelf when a patient needs it.

The End-to-End Commercialization Project is a proof point for a larger idea – that a strategic, resilient, domestic supply chain isn't a nice-to-have. It's national infrastructure. Occam is proud to hold the first link in that chain, and to help ensure that the essential medicines millions of Americans depend on start with an ingredient we can count on.